Interview with Sabine Dandiguian, President, Janssen-Cilag France
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
Address: 14 ave Duquesne, 75007 Paris,France
Tel: 01 40 56 60 65
Web: http://www.sante.gouv.fr/
The Committee Economic Health Products (CEPS) replaced the previous Economic Committee of drugs in 2000. Its missions have been extended to cover health products and services associated with refundable in addition to drugs and it has been amended accordingly.
CEPS contributes to the development of drug policy by putting into practice advice it receives from relevant ministers, applying it notably to price fixing with respect to expenditure and financial regulation of the market. In order to carry this out, the CEPS reaches agreements with businesses on relevant topics, such as drug prices, price evolution, drug reimbursements, regulations concerning the proper use of drugs and sales volumes, as well as methods of participation of enterprises in the implementation of departmental policies.
Janssen-Cilag is involved in not only selling its products in France but research and production as well. As France is a leading subsidiary, can you speak to the importance of…
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
This interview was conducted with Jacques de Chilly and Theirry de Lumley of Aderly hereafter referred to as J.C. and T.L. respectively. Aderly was founded in 1974 in order to…
Most players entered the generic pharmaceutical industry in France in the late 1990s into the 2000s yet Actavis decided to enter much later – in late 2007 – through an…
CIP and GERS have very unique relationships with the pharmaceutical industry. Could you elaborate on the role of these two bodies? Club Inter-pharmaceutique (CIP) is a professional association created in…
As a majority of our readers are American that may be used to a different model of clusters can you explain the unique characteristics of the pôles de compétitivité? The…
Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France…
As president of LEEM, what will be your legacy and what legacy would you like to instill in the organization? A legacy of re-industrialization in the French pharmaceutical and health…
There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these…
Roche has a long history in France and currently enjoys a higher position than its worldwide ranking. Can you elaborate on the importance of this market for the group overall?…
Do you feel the industry has changed more over the past ten years than over the entire 40 years before? It’s an optical illusion. People always have had the feelings…
As the G5 brings together five very different companies – Ipsen, LFB, Pierre Fabre, Sanofi-Aventis, Servier – could you explain the origin behind the creation and the purpose of the…
See our Cookie Privacy Policy Here
